Body mass index ≥23 is a risk factor for insulin resistance and diabetes in Japanese people: A brief report

Okura, Tomohiro; Nakamura, Ryô; Fujioka, Yohei; Kawamoto-Kitao, Sonoko; Ito, Y.; Matsumoto, Kazuhisa; Shoji, Kyoko; Sumi, Keisuke; Matsuzawa, Kazuhiko; Izawa, Shoichiro; Ueta, Etsuko; Kato, Masahiko; Imamura, Teruhiko; Taniguchi, Shin‐ichi; Yamamoto, Kazuhide

doi:10.1371/journal.pone.0201052

Cited by 43 publications

(46 citation statements)

References 25 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the Japanese population, the risk of developing T2DM and insulin resistance increases at a BMI of ≥ 23 kg/m 2 [19]. Therefore, a decrease in body fat induced by weight reduction therapy might help improve insulin resistance in mildly to moderately overweight Japanese patients with T2DM.…”

Section: Discussionmentioning

confidence: 99%

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor

Sugiyama¹,

Jinnouchi²,

Hieshima³

et al. 2020

Cureus

View full text Add to dashboard Cite

The overall goal in the treatment of type 2 diabetes mellitus (T2DM) is remission. However, the effects of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) on remission of T2DM are unknown. We herein report a case involving an overweight 43-year-old man who completely recovered from T2DM after SGLT2i therapy (dapagliflozin at 5 mg/day). In the pretreatment period, he had a body mass index (BMI) of 26.0 kg/m 2 , hemoglobin A1c (HbA1c) concentration of 10.3%, advanced insulin resistance, pancreatic β-cell dysfunction, and fatty liver. Eighteen months after comprehensive therapy, including the administration of an SGLT2i and metformin, his BMI had decreased to 21.3 kg/m 2 and his glycemic control was almost normal (HbA1c of 5.3%) despite discontinuation of all hypoglycemic medications. This report is the first to propose the usefulness of the combination therapy of SGLT2i and metformin for achieving normal body weight and remission of newly diagnosed T2DM in a real-world clinical situation.

show abstract

Section: Discussionmentioning

confidence: 99%

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor

Sugiyama¹,

Jinnouchi²,

Hieshima³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…American diabetes association (ADA) issued a standard for diabetes treatment that lowered the BMI cut-off point for Asian Americans screening for DM from 23 kg/m 2 to 25 kg/m 2 in 2015 [9]. Some study suggested that it was most optimal cut-off point for male and female BMI cut-off points were 23 kg/m 2 and 22 kg/m 2 respectively when screen pre-diabetes (Pre-DM) and DM in middle -aged and older adults [17][18]. In this study, the results show that the sensitivity in screening for DM is respectively 94.08%, 91.59%, 79.75% and 66.04% when BMI take 22, 23, 24 or 25; and YI is respectively 13.76%, 21.37%, 21.51% and 21.25%.…”

Section: Discussionmentioning

confidence: 99%

Optimal Cut-off Points of BMI WC and WHR for Screening of Pre-Diabetes and Diabetes Over 35 Years Old People

Li¹

2019

WJPH

View full text Add to dashboard Cite

Using BMI, WC and WHR to investigate and compare these screening tool for IFG, IGT and diabetes subjects in Shanghai China; and to identify the optimal cutoff points of BMI, WC and WHR for screening pre-diabetes (Pre-DM) and diabetes (DM) over 35 years old people. Totally 3,195 aged 35 years old and above people who attended community epidemiological survey of diabetes mellitus. Using ADA criteria (2010), the participants were classified as normal, Pre-DM or DM according to test results of blood glucose. The area under ROC curve (AUROC) for BMI, WC and WHR were calculated; as well as the sensitivity, specificity and Youden index under different BMI or WHR cutoff points. Among these people, age is (61.07±10.08), and BMI and WHR are respectively (25.12±3.29) and (0.87±0.06). The positive rate of screening of DM is 11.36% and that of Pre-DM is 38.57%. There are correlation between blood glucose and BMI or WHR (p<0.05). With the increase of BMI or WHR cutoff point, the screening sensitivity (YI, Sp and Se) for DM or pre-DM are decreasing; but the area under ROC (AUROC) increases firstly and then decreases (inflection point: WHR≥0.8~0.9 and BMI≥23 for pre-DM, WHR≥0.9 and BMI≥24 for DM). The combined screening efficacy of BMI merged WHR is the best combination choice (cut-off point of BMI and WHR are respectively 23 and 0.8), and YI is the highest. Using HbA1C as standard of judgment seems to be better than blood glucose in screening for DM. BMI≥23, WC≥90 cm or WHR≥0.8 is the optimal cutoff point for screening DM and pre-DM, and the screening efficacy of BMI is better than WC and WHR. BMI merged WHR is the best combination choice (cut-off point of BMI and WHR are respectively 23 and 0.8). HbA1C is better than FBG and OGTT as standard of judgment in screening.

show abstract

“…93,[202][203][204][205][206] There are several risk factors that are assumed to play a role in developing insulin resistance including genetic predisposition, ethnicity, overweight/obesity, and aging. [207][208][209][210][211][212][213] Some candidate genetic variants that make a person more or less probably to develop insulin resistance leading to T2D…”

Section: Insulin Action (Insulin Resistance/low Insulin Sensitivitymentioning

confidence: 99%

“…The importance of insulin resistance in the T2D etiology is well‐established and acknowledged as the most powerful early predictor and therapeutic target for T2D 93,202‐206 . There are several risk factors that are assumed to play a role in developing insulin resistance including genetic predisposition, ethnicity, overweight/obesity, and aging 207‐213 . Some candidate genetic variants that make a person more or less probably to develop insulin resistance leading to T2D have been identified and confirmed in reproducible studies among different populations 214‐218 …”

Section: Overview Of T2dmentioning

confidence: 99%

Genetic predisposition in type 2 diabetes: A promising approach toward a personalized management of diabetes

Sirdah

Reading

2020

Clinical Genetics

View full text Add to dashboard Cite

Diabetes mellitus, also known simply as diabetes, has been described as a chronic and complex endocrine metabolic disorder that is a leading cause of death across the globe. It is considered a key public health problem worldwide and one of four important non-communicable diseases prioritized for intervention through world health campaigns by various international foundations. Among its four categories, Type 2 diabetes (T2D) is the commonest form of diabetes accounting for over 90% of worldwide cases. Unlike monogenic inherited disorders that are passed on in a simple pattern, T2D is a multifactorial disease with a complex etiology, where a mixture of genetic and environmental factors are strong candidates for the development of the clinical condition and pathology. The genetic factors are believed to be key predisposing determinants in individual susceptibility to T2D. Therefore, identifying the predisposing genetic variants could be a crucial step in T2D management as it may ameliorate the clinical condition and preclude complications. Through an understanding the unique genetic and environmental factors that influence the development of this chronic disease individuals can benefit from personalized approaches to treatment. We searched the literature published in three electronic databases: PubMed, Scopus and ISI Web of Science for the current status of T2D and its associated genetic risk variants and discus promising approaches toward a personalized management of this chronic, non-communicable disorder.

show abstract

Body mass index ≥23 is a risk factor for insulin resistance and diabetes in Japanese people: A brief report

Cited by 43 publications

References 25 publications

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor

Optimal Cut-off Points of BMI WC and WHR for Screening of Pre-Diabetes and Diabetes Over 35 Years Old People

Genetic predisposition in type 2 diabetes: A promising approach toward a personalized management of diabetes

Contact Info

Product

Resources

About